Abstract
Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies
Original language | English |
---|---|
Article number | eadl0998 |
Journal | Science Translational Medicine |
Volume | 16 |
Issue number | 753 |
Number of pages | 4 |
ISSN | 1946-6234 |
DOIs | |
Publication status | Published - 2024 |
Bibliographical note
Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.Keywords
- Faculty of Law
- Government Programs
- drug R&D
- new uses
- drug repurposing
- Public private partnership
- Emperical legal studies